Login to Your Account

Pfizer Buying Out Esperion: $1.3B For Cholesterol Drugs

By Randall Osborne

Tuesday, December 23, 2003
The winter solstice, once celebrated for its promise of steadily longer days, brought sunny news for Esperion Therapeutics Inc. this year in the form of a $1.3 billion buyout by Pfizer Inc. - at $35 per share, a 54 percent premium to the company's average closing share price during the previous 20 days. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription